Ann Coloproctol.  2014 Aug;30(4):201-204. 10.3393/ac.2014.30.4.201.

Regression of Colonic Adenomas After Treatment With Sulindac in Familial Adenomatous Polyposis: A Case With a 2-Year Follow-up Without a Prophylactic Colectomy

• Kim KY
• Jeon SW
• Park JG
• Yu CH
• Jang SY
• Lee JK
• Hwang HY

• KMID: 2169745
• DOI: http://doi.org/10.3393/ac.2014.30.4.201

Abstract

Familial adenomatous polyposis (FAP) is an autosomal dominant disorder characterized by hundreds of colorectal adenomatous polyps that progress to colorectal cancer. Management of patients with FAP is with a total colectomy. Chemopreventive strategies have been studied in FAP patients in an effort to delay the development of adenomas in the upper and the lower gastrointestinal tract and to prevent recurrence of adenomas in the retained rectum of patients after prophylactic surgery. Sulindac, a nonsteroidal anti-inflammatory drug, causes regression of colorectal adenomas in the retained rectal segment of FAP patients. However, evidence regarding long-term use of this therapy and its effect on the intact colon has been insufficient. We report a case in which the long-term use of sulindac was effective in reducing the size and the number of colonic polyps in patients with FAP without a prophylactic colectomy and polypectomy; we also present a review of the literature.

Keyword

Adenomatous polyposis coli; Sulindac; Therapy; Chemoprevention

MeSH Terms

Adenoma*
Adenomatous Polyposis Coli*
Adenomatous Polyps
Chemoprevention
Colectomy*
Colon*
Colonic Polyps
Colorectal Neoplasms
Follow-Up Studies*
Humans
Lower Gastrointestinal Tract
Rectum
Recurrence
Sulindac*
Sulindac